• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

byJessie WillisandTeddy Guo
September 8, 2021
in Chronic Disease, Hematology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events.

2. There was a 65% overall response rate seen in patients on the recommended dosage of teclistamab that persisted and increased overtime.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Multiple myeloma is the second most common blood cancer in the world. There is currently no curative therapy for multiple myeloma; however, the rapid development of novel immunotherapies has prolonged survival in the past 5 years. This phase 1 study focuses on determining the recommended phase 2 dosage of a new biologic, teclistamab, a BCMA x CD3 T-cell redirecting bispecific antibody. 157 refractive multiple myeloma patients were enrolled into the study and were randomized into either intravenous (IV) or subcutaneous treatment. A recommended phase 2 dosage was theorized using existing drug data of 1500 ug/kg teclistamab subcutaneously once per week. While two dose-limiting events occurred in IV patients, no dose-limiting toxicities were seen at the recommended phase 2 dose. The most common adverse events were cytokine release syndrome and neutropenia. In the patients on recommended dose, just over half achieved a partial or better response. Limitations of this study included the low sample size and single-arm design. Nevertheless, this study demonstrated the safety and efficacy of recommended dose for the ongoing phase 2 study.

Click to read the study in The Lancet

Relevant Reading: How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

RELATED REPORTS

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

FDA grants priority review for iberdomide-based myeloma regimen

FDA approvedFor multiple myeloma: Zenbexus (iberdomide), Aug 13, 2026→

In-Depth [randomized controlled trial]: This open-label, single-arm, phase 1 drug study of the biologic, teclistamab, is an ongoing study in 12 hospitals centers in USA, Spain, France, the Netherlands, and Sweden. 157 patients were separated into two cohorts of  IV (n=84) and subcutaneous (n=73) administration. The median age of the patients was 63 years and 54% were male. The eligible patient population had relapsed, refractory, or treatment-resistant multiple myeloma. 40 patients were put on the phase 2 recommended subcutaneous dosage of 1500 ug/kg once per week. No dose-limiting toxicities were seen in this population, but adverse events such as cytokine release syndrome (28/40) and neutropenia (26/40) did occur. In the recommended dose group, overall response rate was 65% (95% CI 48-79) and the median time to the first confirmed response was 1 month. No median duration of response was reached. 85% (22/26) of the responders were alive after the 7.1 median follow-up period.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hematologic cancerhematologic malignancyhematologic malignant neoplasmshigh-risk multiple myelomamultiple myelomarelapsed and refractory multiple myelomarelapsed or refractory multiple myelomarelapsed refractory multiple myelomateclistamab
Previous Post

Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing

Next Post

Association of sleep duration with all-cause mortality in East Asian adults

RelatedReports

Abstract representation of hematological cells with a fluid bag and pill, indicating targeted therapy for leukemia or multiple myeloma.
Chronic Disease

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

September 28, 2026
Variation noted across pre- and post-marketing studies for FDA approved devices
Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026
Heart failure collage: an engraved heart with teal ventricles above a folded patchwork quilt, a teacup and house slippers
Weekly Rewinds

2 Minute Medicine Rewind

January 13, 2026
Multiple myeloma testing collage: a smiling older man with a white beard, a round slice of spongy bone and magnified cells
Chronic Disease

Pre-maintenance positron emission tomography/computed tomography and bone marrow multiparameter flow cytometry are important for prognostication in multiple myeloma treated with daratumumab

January 13, 2026
Next Post

Association of sleep duration with all-cause mortality in East Asian adults

Association between intimate partner violence during pregnancy and risk of preterm birth 

#VisualAbstract: Continuous electrocardiogram monitoring following discharge detects atrial fibrillation in postoperative cardiac patients

#VisualAbstract: Continuous electrocardiogram monitoring following discharge detects atrial fibrillation in postoperative cardiac patients

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.